Patients with a current or previous history of cardiac impairment; Patients known to have hypersensitivity to the drug; Patients already treated with maximal cumulative doses of other anthracyclines such as Epirubicin (500 mg/m2-Surface area) or daunorubicin (25 mg/kg: total dose); Patients with heart disease.